Country websites:

Attention

The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

Not all products are cleared or available for sale in all countries.

By clicking on the button "Accepted and Confirmed" you assure that you have taken note of this information and that you are a healthcare professional.

MONET®

Effective lipoprotein filtration with MONET®

MONET ® lipoprotein filtration

MONET® stands for Membrane Filtration Optimized Novel Extracorporeal Treatment.

Lipoprotein filtration with MONET® is used to reduce high molecular weight molecules such as:

  • High molcular weight lipoproteins — specifically LDL-C and Lp(a)
  • High molcular weight plasma proteins that are rheological relevant

The MONET® plasma fractionator contains a Fresenius Polysulfone® membrane, enhanced for use in lipoprotein filtration.

The membrane has the same excellent biocompatibilities as other Fresenius filters and is the result of our continuous product improvement procedures.

MONET® treatment procedure

During lipoprotein filtration, venovenous or AV fistula access can be used. The procedure consists of two steps: In step one, the plasma is separated from whole blood by plasma filtration or centrifugation. In step two, the plasma is passed through a second filter, the MONET® plasma fractionator. MONET® retains high-molecular components, such as:

  • Low density lipoprotein (LDL)
  • Very low density lipoprotein (VLDL)
  • Lp(a)
  • Triglycerides
  • Fibrinogen
  • IgM and IgA

Finally, the purified plasma is combined again with the whole blood and returned to the patient.

MONET plasma fractionation
MONET® runs as a plasma fractionator

Benefits of treatment with MONET®

Anticoagulation can be customized according to the patient’s needs

Clinical setup

MONET® can be carried out with:

  • Either the haemoadsorption machine Art Universal
  • Or a blood cell separator / centrifuge (e.g. COM.TEC®)
MONET clinical setup
MONET® clinical setup

Related therapies

1. Julius U et al.; Therapeutic Apheresis and Dialysis Apr. 2013; 17(2): 179–84.
2. Julius U et al.; Atherosclerosis Supplements May 2015; 18: 95–102